Altivera Medical adds three directors as it pushes governance and growth

By AI, Created 10:56 PM UTC, June 02, 2026, /AGP/ – Altivera Medical Holdings has named Lt. Gen. (Ret.) Ronald J. Place, MD, Bret Wise and David Ashley Lee to its board as the MedTech company tries to strengthen oversight and rebuild trust after its Zynex acquisition. The appointments come as TRICARE has reinstated payment for Zynex claims and Altivera looks to scale its pain management and recovery business.

Why it matters: - Altivera Medical is adding senior clinical, operational and financial leadership to its board as the company tries to strengthen governance and support long-term growth. - The move comes during a reset period for Altivera after its acquisition of Zynex and amid efforts to rebuild trust with regulators and government partners. - Board credibility matters for a MedTech company selling recovery and pain-management technologies to patients, clinicians and health systems.

What happened: - Altivera Medical Holdings announced the appointment of Lt. Gen. (Ret.) Ronald J. Place, MD, Bret Wise and David Ashley Lee to its Board of Directors. - The company said the appointments reflect continued investment in governance, operational excellence and strategic growth. - Altivera said the new directors will join Jake Mercer, chair of the board.

The details: - Dr. Place is regional president and chief executive officer of Avera McKennan Hospital and University Health Center in Sioux Falls, South Dakota. - Dr. Place spent nearly 40 years in the U.S. Army and rose to lieutenant general. - Dr. Place served as the third director of the Defense Health Agency. - In that role, Dr. Place led care delivery for millions of service members, retirees and family members. - Dr. Place also oversaw the TRICARE Health Plan, which has nearly 10 million members. - Dr. Place oversaw the largest integrated medical education program in the country and a multi-billion-dollar medical research and sustainment program. - Dr. Place is board certified in general surgery and colorectal surgery. - Dr. Place is a clinical professor of surgery at the Uniformed Services University of Health Sciences and the University of South Dakota Sanford School of Medicine. - Altivera said Wise brings more than four decades of operational and financial leadership in the medical device industry. - Wise previously served as chair and chief executive officer of Dentsply International. - Altivera said Lee brings 40 years of financial and operational management experience in MedTech. - Lee previously served as EVP, COO and CFO at Artivion, Inc., formerly CryoLife. - Altivera said the three new directors and Mercer bring more than 130 years of combined leadership experience in healthcare, MedTech and finance. - Steven Dyson, Altivera’s CEO, said Place’s clinical background aligns with the company’s technology platform and reinforces its focus on integrity, transparency, compliance and patient care. - Dr. Place said Altivera is entering a defining chapter centered on trust, patient outcomes and a stronger foundation for the future. - Dr. Place said recovery has been treated as an afterthought for too long and that patients often leave clinical settings without continuity of care. - Dr. Place said the NexWave is one of the most compelling recovery tools he has seen and called it an evidence-based solution. - Altivera said the company focuses on non-invasive technologies for pain management, rehabilitation and recovery across musculoskeletal and neuromuscular care. - Altivera said its technologies include clinically proven electrotherapy, monitoring and rehabilitation products. - Altivera said all products and services are provided by Zynex Medical Inc., a wholly owned subsidiary. - Altivera directed readers to more information. - Altivera also linked to its LinkedIn page.

Between the lines: - Altivera is signaling that its board should function as part clinical credibility, part operational repair and part commercial discipline. - Adding a former three-star military physician and two MedTech executives suggests the company wants outside expertise that can support both compliance and growth. - The mention of TRICARE payment reinstatement and the bankruptcy-court-approved acquisition shows Altivera is still working through the business fallout tied to Zynex.

What’s next: - Altivera will rely on the expanded board as it advances its commercial and governance agenda. - The company is likely to keep emphasizing clinical outcomes, compliance and trust as it tries to rebuild momentum after the acquisition. - Altivera says it will continue to market its recovery technologies through Zynex Medical Inc.

The bottom line: - Altivera is betting that heavyweight board additions and a cleaner operating story will help accelerate its next phase of growth.